Tapewire

Nasdaq · USD

VRTX

VERTEX PHARMACEUTICALS INC / MA

Export transactions ↓
Tapewire entity
2875
SEC CIK
0000875320
Parsed reports
2,554

Last 12 months

Inside the activity.

0 purchase rows · 93 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202506
Dec 2025016
Jan 202602
Feb 2026049
Mar 202605
Apr 202601
May 202606
Jun 202605
Jul 202603
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
February 12, 2025 Filed Feb 14, 2025 21:11 UTC
Bozic CarmenEVP and CMO
GrantCommon Stock 5,546 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000065 · wk-form4_1739567507.xml · nonDerivative · entry 1

Bozic Carmen · CIK 0001790029 · EVP and CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,853

F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2026.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 21:13 UTC
Kewalramani ReshmaDirector · CEO & President
GrantCommon Stock 19,015 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000067 · wk-form4_1739567593.xml · nonDerivative · entry 1

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,933

F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2026.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 21:17 UTC
LEIDEN JEFFREY MDirector · Executive Chairman
GrantCommon Stock 7,209 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000071 · wk-form4_1739567825.xml · nonDerivative · entry 1

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,617

F1 · shares: Restricted stock unit award that fully vested upon grant.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 21:14 UTC
Sachdev AmitEVP Chief Patient & Ext Af Off
GrantCommon Stock 6,211 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000069 · wk-form4_1739567669.xml · nonDerivative · entry 1

Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,802

F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2026.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 21:18 UTC
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
GrantCommon Stock 6,211 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000073 · wk-form4_1739567930.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,232

F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2026.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 21:21 UTC
WAGNER CHARLES F JREVP & Chief Financial Officer
GrantCommon Stock 6,655 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000075 · wk-form4_1739568057.xml · nonDerivative · entry 1

WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,534

F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2026.

Read SEC document
February 11, 2025 Filed Feb 12, 2025 21:24 UTC
Ambrose KristenSVP & Chief Accounting Officer
SaleCommon Stock 1,376 $459.83 $632,726.08
Disclosure

SEC source: 0000875320-25-000033 · wk-form4_1739395442.xml · nonDerivative · entry 2

Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,953

F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2024.

Read SEC document
February 11, 2025 Filed Feb 12, 2025 21:29 UTC
Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.
SaleCommon Stock 1,747 $459.83 $803,323.01
Disclosure

SEC source: 0000875320-25-000037 · wk-form4_1739395783.xml · nonDerivative · entry 2

Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,225

F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 02/22/2024.

Read SEC document
February 11, 2025 Filed Feb 12, 2025 21:36 UTC
Biller JonathanEVP and Chief Legal Officer
SaleCommon Stock 3,433 $459.87 $1,578,733.71
Disclosure

SEC source: 0000875320-25-000039 · wk-form4_1739396180.xml · nonDerivative · entry 2

Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,330

F1 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/13/2024.

F2 · price: Mr. Biller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $459.87 (range $459.83 to $460.00).

Read SEC document
February 11, 2025 Filed Feb 12, 2025 21:50 UTC
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
SaleCommon Stock 310 $459.83 $142,547.30
Disclosure

SEC source: 0000875320-25-000048 · wk-form4_1739397030.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,021

F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:21 UTC
ALTSHULER DAVIDEVP, Chief Scientific Officer
Tax withholdingCommon Stock 2,142 $467.98 $1,002,413.16
Disclosure

SEC source: 0000875320-25-000031 · wk-form4_1739395266.xml · nonDerivative · entry 1

ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,099

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:24 UTC
Ambrose KristenSVP & Chief Accounting Officer
Tax withholdingCommon Stock 591 $467.98 $276,576.18
Disclosure

SEC source: 0000875320-25-000033 · wk-form4_1739395442.xml · nonDerivative · entry 1

Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,329

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:26 UTC Tax withholdingCommon Stock 3,220 $467.98 $1,506,895.60
Disclosure

SEC source: 0000875320-25-000035 · wk-form4_1739395597.xml · nonDerivative · entry 1

Arbuckle Stuart A · CIK 0001557290 · EVP, COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,543

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:29 UTC
Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.
Tax withholdingCommon Stock 876 $467.98 $409,950.48
Disclosure

SEC source: 0000875320-25-000037 · wk-form4_1739395783.xml · nonDerivative · entry 1

Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,972

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:36 UTC
Biller JonathanEVP and Chief Legal Officer
Tax withholdingCommon Stock 1,632 $467.98 $763,743.36
Disclosure

SEC source: 0000875320-25-000039 · wk-form4_1739396180.xml · nonDerivative · entry 1

Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,763

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:38 UTC
Bozic CarmenEVP and CMO
Tax withholdingCommon Stock 2,142 $467.98 $1,002,413.16
Disclosure

SEC source: 0000875320-25-000041 · wk-form4_1739396310.xml · nonDerivative · entry 1

Bozic Carmen · CIK 0001790029 · EVP and CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,307

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:46 UTC
Kewalramani ReshmaDirector · CEO & President
Tax withholdingCommon Stock 8,300 $467.98 $3,884,234.00
Disclosure

SEC source: 0000875320-25-000044 · wk-form4_1739396757.xml · nonDerivative · entry 1

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,918

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:48 UTC
Sachdev AmitEVP Chief Patient & Ext Af Off
Tax withholdingCommon Stock 2,056 $467.98 $962,166.88
Disclosure

SEC source: 0000875320-25-000046 · wk-form4_1739396879.xml · nonDerivative · entry 1

Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,591

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:50 UTC
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
Tax withholdingCommon Stock 2,143 $467.98 $1,002,881.14
Disclosure

SEC source: 0000875320-25-000048 · wk-form4_1739397030.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,331

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:52 UTC
WAGNER CHARLES F JREVP & Chief Financial Officer
Tax withholdingCommon Stock 2,649 $467.98 $1,239,679.02
Disclosure

SEC source: 0000875320-25-000050 · wk-form4_1739397137.xml · nonDerivative · entry 1

WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,879

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:07 UTC
ALTSHULER DAVIDEVP, Chief Scientific Officer
GrantCommon Stock 7,114 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000005 · wk-form4_1738876056.xml · nonDerivative · entry 2

ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,241

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:07 UTC
ALTSHULER DAVIDEVP, Chief Scientific Officer
GrantCommon Stock 12,314 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000005 · wk-form4_1738876056.xml · nonDerivative · entry 1

ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,127

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:15 UTC
Ambrose KristenSVP & Chief Accounting Officer
GrantCommon Stock 1,854 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000007 · wk-form4_1738876523.xml · nonDerivative · entry 2

Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,920

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:15 UTC
Ambrose KristenSVP & Chief Accounting Officer
GrantCommon Stock 2,566 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000007 · wk-form4_1738876523.xml · nonDerivative · entry 1

Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,066

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:18 UTC GrantCommon Stock 8,448 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000009 · wk-form4_1738876713.xml · nonDerivative · entry 2

Arbuckle Stuart A · CIK 0001557290 · EVP, COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,763

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:18 UTC GrantCommon Stock 14,624 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000009 · wk-form4_1738876713.xml · nonDerivative · entry 1

Arbuckle Stuart A · CIK 0001557290 · EVP, COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,315

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:21 UTC
Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.
GrantCommon Stock 4,744 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000011 · wk-form4_1738876909.xml · nonDerivative · entry 2

Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,848

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:21 UTC
Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.
GrantCommon Stock 5,132 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000011 · wk-form4_1738876909.xml · nonDerivative · entry 1

Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,104

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:32 UTC
Biller JonathanEVP and Chief Legal Officer
GrantCommon Stock 4,744 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000014 · wk-form4_1738877513.xml · nonDerivative · entry 1

Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,395

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:35 UTC
Bozic CarmenEVP and CMO
GrantCommon Stock 5,928 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000016 · wk-form4_1738877728.xml · nonDerivative · entry 2

Bozic Carmen · CIK 0001790029 · EVP and CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,449

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:35 UTC
Bozic CarmenEVP and CMO
GrantCommon Stock 10,262 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000016 · wk-form4_1738877728.xml · nonDerivative · entry 1

Bozic Carmen · CIK 0001790029 · EVP and CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,521

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:37 UTC
Kewalramani ReshmaDirector · CEO & President
GrantCommon Stock 20,328 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000018 · wk-form4_1738877851.xml · nonDerivative · entry 2

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,218

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:37 UTC
Kewalramani ReshmaDirector · CEO & President
GrantCommon Stock 29,118 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000018 · wk-form4_1738877851.xml · nonDerivative · entry 1

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,890

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:38 UTC
LEIDEN JEFFREY MDirector · Executive Chairman
GrantCommon Stock 15,414 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000020 · wk-form4_1738877930.xml · nonDerivative · entry 1

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,408

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/17/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:41 UTC
Sachdev AmitEVP Chief Patient & Ext Af Off
GrantCommon Stock 7,114 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000022 · wk-form4_1738878100.xml · nonDerivative · entry 2

Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,647

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:41 UTC
Sachdev AmitEVP Chief Patient & Ext Af Off
GrantCommon Stock 8,210 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000022 · wk-form4_1738878100.xml · nonDerivative · entry 1

Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,533

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:43 UTC
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
GrantCommon Stock 7,114 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000024 · wk-form4_1738878214.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,474

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:43 UTC
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
GrantCommon Stock 10,262 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000024 · wk-form4_1738878214.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,360

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:45 UTC
WAGNER CHARLES F JREVP & Chief Financial Officer
GrantCommon Stock 7,114 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000026 · wk-form4_1738878299.xml · nonDerivative · entry 2

WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,528

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:45 UTC
WAGNER CHARLES F JREVP & Chief Financial Officer
GrantCommon Stock 10,262 $0.00 $0.00
Disclosure

SEC source: 0000875320-25-000026 · wk-form4_1738878299.xml · nonDerivative · entry 1

WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,414

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025.

Read SEC document
January 15, 2025 Filed Jan 17, 2025 21:04 UTC GrantDeferred Stock Units · Derivative 111.654 $420.31 $46,929.29
Disclosure

SEC source: 0000875320-25-000002 · wk-form4_1737147865.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,144.986

Underlying: Common Stock · 111.654 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:08 UTC
ALTSHULER DAVIDEVP, Chief Scientific Officer
SaleCommon Stock 15 $478.56 $7,178.40
Disclosure

SEC source: 0000875320-24-000229 · wk-form4_1732050530.xml · nonDerivative · entry 1

ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,813

F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024.

Read SEC document
November 11, 2024 Filed Nov 13, 2024 21:15 UTC
WAGNER CHARLES F JREVP & Chief Financial Officer
SaleCommon Stock 3,000 $518.27 $1,554,810.00
Disclosure

SEC source: 0000875320-24-000227 · wk-form4_1731532506.xml · nonDerivative · entry 1

WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,137

F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2024.

Read SEC document
November 08, 2024 Filed Nov 12, 2024 21:08 UTC
Kewalramani ReshmaDirector · CEO & President
SaleCommon Stock 15,198 $515.00 $7,826,970.00
Disclosure

SEC source: 0000875320-24-000225 · wk-form4_1731445703.xml · nonDerivative · entry 1

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,772

F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 02/07/2024.

Read SEC document
October 15, 2024 Filed Oct 17, 2024 20:12 UTC GrantDeferred Stock Units · Derivative 90.32 $484.39 $43,750.10
Disclosure

SEC source: 0000875320-24-000216 · wk-form4_1729195965.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,033.332

Underlying: Common Stock · 90.32 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
October 02, 2024 Filed Oct 3, 2024 20:12 UTC
Biller JonathanEVP and Chief Legal Officer
SaleCommon Stock 999 $461.66 $461,198.34
Disclosure

SEC source: 0000875320-24-000214 · wk-form4_1727986328.xml · nonDerivative · entry 2

Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,651

F1 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/13/2024.

Read SEC document
October 01, 2024 Filed Oct 3, 2024 20:12 UTC
Biller JonathanEVP and Chief Legal Officer
Tax withholdingCommon Stock 630 $466.84 $294,109.20
Disclosure

SEC source: 0000875320-24-000214 · wk-form4_1727986328.xml · nonDerivative · entry 1

Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,650

Read SEC document
August 30, 2024 Filed Sep 4, 2024 20:12 UTC Exercise / conversionStock Option (Right to Buy) · Derivative 646 $0.00 Strike: $152.74 $0.00
Disclosure

SEC source: 0000875320-24-000211 · wk-form4_1725480753.xml · derivative · entry 3

Bhatia Sangeeta N. · CIK 0001643921 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 646 shares

Expires 2028-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
August 30, 2024 Filed Sep 4, 2024 20:12 UTC SaleCommon Stock 646 $500.00 $323,000.00
Disclosure

SEC source: 0000875320-24-000211 · wk-form4_1725480753.xml · nonDerivative · entry 2

Bhatia Sangeeta N. · CIK 0001643921 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,435

F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2024.

Read SEC document
August 30, 2024 Filed Sep 4, 2024 20:12 UTC Exercise / conversionCommon Stock 646 $152.74 $98,670.04
Disclosure

SEC source: 0000875320-24-000211 · wk-form4_1725480753.xml · nonDerivative · entry 1

Bhatia Sangeeta N. · CIK 0001643921 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,081

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.